U057 When to Put Down the Scalpel: Non-surgical Therapies for Skin Cancer
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session is directed to general dermatologists. We will cover key aspects of non-surgical approaches in non-melanoma skin cancer treatment, including patient selection, counseling, and expected outcomes. We will cover the following non-surgical treatments and provide clinical pearls: topical medications, cryotherapy, photodynamic therapy, intralesional treatments, and systemic options. We also will cover consideration of active surveillance and chemoprevention in select patients. We will describe patient selection for these non-surgical therapies, including consideration of co-morbidities, aversion to surgery, low-risk tumors, high tumor burden, and eruptive KAs.
LEARNING OBJECTIVES
Recognize localized skin cancer cases that would benefit most from non-surgical treatment
Select the optimal non-surgical treatment for localized skin cancer patients
Identify the risks and benefits of active surveillance for localized skin cancer
SCHEDULE
12:00 PM
Localized Non-Surgical Treatments for Keratinocyte Carcinoma
Abigail Baird Waldman, MD, FAAD
12:20 PM
Systemic Therapies for Keratinocyte Carcinoma
Emily S Ruiz, MD, FAAD
12:40 PM
Prevention and Active Surveillance for Keratinocyte Carcinoma
Rebecca I Hartman, MD, MPH, FAAD
SPEAKERS
Rebecca I Hartman, MD, MPH, FAAD
Emily S Ruiz, MD, FAAD
Abigail Baird Waldman, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees); Zura Bio – Data Safety Monitoring Board(Fees);
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
Abigail Baird Waldman, MD, FAAD
No financial relationships exist with ineligible companies.